Health Utilities for Non-melanoma Skin Cancers and Pre-cancerous Lesions: A Systematic Review

Overview

Journal Skin Health Dis

Publisher Oxford University Press

Specialty Dermatology

Date 2022 Jun 6

PMID 35663144

Authors

C So

A E Cust

L G Gordon

R L Morton

K Canfell

P Ngo

M Dieng

K McLoughlin

C Watts

Affiliations

Soon will be listed here.

Abstract

Background: Non-melanoma skin cancers (NMSCs) are common and consume many healthcare resources. A health utility is a single preference-based value for assessing health-related quality of life, which can be used in economic evaluations. There are scarce data on health utilities for NMSCs.

Objectives: Using a systematic review approach, we synthesized the current data on NMSC-related health utilities.

Methods: A systematic review of studies of NMSC-related health utilities was conducted in Medline, Embase, and Cochrane databases. Data were extracted based on the protocol and a quality assessment was performed for each study.

Results: The protocol resulted in 16 studies, involving 121 621 participants. Mean utility values across the studies ranged from 0.56 to 1 for undifferentiated NMSC, 0.84 to 1 for actinic keratosis, 0.45 to 1 for squamous cell carcinoma, and 0.67 to 1 for basal cell carcinoma. There was considerable variability in utilities by type of cancer, stage of diagnosis, time to treatment, treatment modality, and quality of life instrument or method. Utility values were predominantly based on the EuroQol 5-dimension instrument and ranged from 0.45 to 0.96, while other measurement methods produced values ranging from 0.67 to 1. Lower utility values were observed for advanced cancers and for the time period during and immediately after treatment, after which values gradually returned to pre-treatment levels.

Conclusions: Most utility values clustered around relatively high values of 0.8 to 1, suggesting small decrements in quality of life associated with most NMSCs and their precursors. Variability in utilities indicates that careful characterization is required for measures to be used in economic evaluations.

Citing Articles

Liu Q, Sha M, Xue B, Shen L, Li G, Cheng X Ann Transl Med. 2023; 11(3):150.

PMID: 36846015 PMC: 9951022. DOI: 10.21037/atm-22-6654.

Health utilities for non-melanoma skin cancers and pre-cancerous lesions: A systematic review.

So C, Cust A, Gordon L, Morton R, Canfell K, Ngo P Skin Health Dis. 2022; 1(3):e51.

PMID: 35663144 PMC: 9060093. DOI: 10.1002/ski2.51.

References

Wong W, Morton R . Elective management of cervical and parotid lymph nodes in stage N0 cutaneous squamous cell carcinoma of the head and neck: a decision analysis. Eur Arch Otorhinolaryngol. 2013; 271(11):3011-9. DOI: 10.1007/s00405-013-2857-6. View

Puig S, Berrocal A . Management of high-risk and advanced basal cell carcinoma. Clin Transl Oncol. 2015; 17(7):497-503. PMC: 4495248. DOI: 10.1007/s12094-014-1272-9. View

Philipp-Dormston W, Muller K, Novak B, Stromer K, Termeer C, Hammann U . Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression. J Eur Acad Dermatol Venereol. 2017; 32(7):1138-1146. PMC: 6032898. DOI: 10.1111/jdv.14703. View

Brazier J, Ara R, Azzabi I, Busschbach J, Chevrou-Severac H, Crawford B . Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. Value Health. 2019; 22(3):267-275. DOI: 10.1016/j.jval.2019.01.004. View

Lomas A, Leonardi-Bee J, Bath-Hextall F . A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012; 166(5):1069-80. DOI: 10.1111/j.1365-2133.2012.10830.x. View

Migden M, Rischin D, Schmults C, Guminski A, Hauschild A, Lewis K . PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018; 379(4):341-351. DOI: 10.1056/NEJMoa1805131. View

Tran A, Fogarty G, Nowak A, Espinoza D, Rowbotham N, Stockler M . A systematic review and meta-analysis of utility estimates in melanoma. Br J Dermatol. 2017; 178(2):384-393. DOI: 10.1111/bjd.16098. View

Pil L, Hoorens I, Vossaert K, Kruse V, Tromme I, Speybroeck N . Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure. Prev Med. 2016; 93:177-182. DOI: 10.1016/j.ypmed.2016.10.005. View

Bertino G, Sersa G, Terlizzi F, Occhini A, Plaschke C, Groselj A . European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. Eur J Cancer. 2016; 63:41-52. DOI: 10.1016/j.ejca.2016.05.001. View

10.

de Freitas C, Santos A, Bittner G, Sanabria B, Levenhagen M, Hans-Filho G . Nonmelanoma Skin Cancer at Critical Facial Sites: Results and Strategies of the Surgical Treatment of 102 Patients. J Skin Cancer. 2019; 2019:4798510. PMC: 6617868. DOI: 10.1155/2019/4798510. View

11.

Torrance G, Feeny D, Furlong W, Barr R, Zhang Y, Wang Q . Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care. 1996; 34(7):702-22. DOI: 10.1097/00005650-199607000-00004. View

12.

Gordon L, Elliott T, Olsen C, Pandeya N, Whiteman D . Multiplicity of skin cancers in Queensland and their cost burden to government and patients. Aust N Z J Public Health. 2017; 42(1):86-91. DOI: 10.1111/1753-6405.12738. View

13.

Muller K, Karrer S, Szeimies R, Steinbauer J, Kohl E, Steinbauer D . Quality of life assessment in patients with nonmelanoma skin cancer - psychometric validation of the EORTC QLQ-C30 questionnaire. J Dtsch Dermatol Ges. 2017; 15(11):1090-1100. DOI: 10.1111/ddg.13357. View

14.

So C, Cust A, Gordon L, Morton R, Canfell K, Ngo P . Health utilities for non-melanoma skin cancers and pre-cancerous lesions: A systematic review. Skin Health Dis. 2022; 1(3):e51. PMC: 9060093. DOI: 10.1002/ski2.51. View

15.

Wu X, Elkin E, Marghoob A . Burden of basal cell carcinoma in USA. Future Oncol. 2015; 11(22):2967-74. DOI: 10.2217/fon.15.180. View

16.

Seidler A, Bayoumi A, Goldstein M, Cruz Jr P, Chen S . Willingness to pay in dermatology: assessment of the burden of skin diseases. J Invest Dermatol. 2012; 132(7):1785-90. DOI: 10.1038/jid.2012.50. View

17.

Gaulin C, Sebaratnam D, Fernandez-Penas P . Quality of life in non-melanoma skin cancer. Australas J Dermatol. 2014; 56(1):70-6. DOI: 10.1111/ajd.12205. View

18.

Eide M, Krajenta R, Johnson D, Long J, Jacobsen G, Asgari M . Identification of patients with nonmelanoma skin cancer using health maintenance organization claims data. Am J Epidemiol. 2009; 171(1):123-8. PMC: 2796985. DOI: 10.1093/aje/kwp352. View

19.

Hanke W, Norlin J, Knudsen K, Larsson T, Stone S . Quality of life in treatment of AK: Treatment burden of ingenol mebutate gel is small and short lasting. J Dermatolog Treat. 2016; 27(5):450-5. DOI: 10.3109/09546634.2016.1160024. View

20.

Both H, Essink-Bot M, Busschbach J, Nijsten T . Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007; 127(12):2726-39. DOI: 10.1038/sj.jid.5701142. View